ImExHS Limited
ImExHS Limited
- P/E ratio
- 88.57
Your view on IME.AX
Overview
What the company does, where it operates, and who runs it.
About ImExHS Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- German Arango
- Headquarters
- 32 Martin Place, Sydney, NSW, AU
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- German Arango
- Headquarters
- 32 Martin Place, Sydney, NSW, AU
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia.
The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information management platforms for disciplines such as radiology, cardiology, and pathology, alongside a robust picture archiving and communication system (PACS).
Its principal software solutions include AQUILA for radiology, ALULA for pathology, and Antero for cardiology. Moreover, ImExHS offers STELLA.I, a suite of artificial intelligence tools hosted in the cloud, crafted to bolster diagnostic capabilities for medical professionals.
The company further extends outsourced radiology and teleradiology services to hospitals and various other healthcare entities. Established in 2001, ImExHS Limited operates from its base in Mascot, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for ImExHS Limited. Starting points for ImExHS Limited: P/E 88.6, beta 0.81 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for ImExHS Limited. ImExHS Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for ImExHS Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | AUD 0.00 | −AUD 0.00 | AUD 0.01 |
| Low estimate | AUD 0.00 | −AUD 0.00 | AUD 0.01 |
| High estimate | AUD 0.00 | −AUD 0.00 | AUD 0.01 |
| No. of analysts | 0 | 1 | 1 |
| Year-ago EPS | −AUD 0.03 | −AUD 0.06 | — |
| Growth | +100.0% | +99.7% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | AUD 16.15M | AUD 32.80M | AUD 35.70M |
| Low estimate | AUD 16.15M | AUD 32.80M | AUD 35.70M |
| High estimate | AUD 16.15M | AUD 32.80M | AUD 35.70M |
| No. of analysts | 1 | 1 | 1 |
| Year-ago revenue | AUD 10.87M | AUD 28.97M | — |
| Growth | +48.7% | +13.2% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for ImExHS Limited. ImExHS Limited has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| CBL.AXControl Bionics Limited | Healthcare | Medical - Devices | — | ||
| ENL.AXEnlitic, Inc. | Healthcare | Medical - Healthcare Information Services | — | ||
| HIQ.AXHITIQ Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| ICR.AXIntelicare Holdings Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| NC6.AXNanollose Limited | Healthcare | Biotechnology | — | ||
| NTI.AXNeurotech International Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| WUXIFWuXi AppTec Co., Ltd. | Healthcare | OTC | $39.8B | ||
| XGNExagen Inc. | Healthcare | NASDAQ | $99.5M | ||
| SKHHYSonic Healthcare Limited | Healthcare | OTC | $8.2B | ||
| SLDXStella Diagnostics Inc. | Healthcare | OTC | $1.4M | ||
| SPDESpeedus Corp. | Healthcare | OTC | $416 | ||
| SZLSFStageZero Life Sciences Ltd. | Healthcare | OTC | $61,766 | ||
| TDSGFTelo Genomics Corp. | Healthcare | OTC | $3.8M | ||
| TELO.VTelo Genomics Corp. | Healthcare | TSXV | $4.0M | ||
| THOXFBioPorto A/S | Healthcare | OTC | $73.8M | ||
| TMOThermo Fisher Scientific Inc. | Healthcare | NYSE | $256.7B | ||
| TMO.NEThermo Fisher Scientific Inc. | Healthcare | NEO | — | ||
| TOMDFTodos Medical Ltd. | Healthcare | OTC | $14,081 | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for ImExHS Limited. Coverage tracks ImExHS Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of ImExHS Limited.